These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 34823523)
21. Developing and Evaluating the HRM Technique for Identifying Cytochrome P450 2D6 Polymorphisms. Lu HC; Chang YS; Chang CC; Lin CH; Chang JG J Clin Lab Anal; 2015 May; 29(3):220-5. PubMed ID: 24798984 [TBL] [Abstract][Full Text] [Related]
22. Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China. Liu H; Yang HL; Xu JW; Wang JZ; Nie RH; Li CF Malar J; 2013 Nov; 12():409. PubMed ID: 24215565 [TBL] [Abstract][Full Text] [Related]
23. Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients. Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Cho SH; Lee SE; Kwon JR; Park S; Kim M; Oh HS; Kim YC; Kim MJ; Yeom JS Malar J; 2022 Oct; 21(1):289. PubMed ID: 36217154 [TBL] [Abstract][Full Text] [Related]
24. A study on relapse/re-infection rate of Plasmodium vivax malaria and identification of the predominant genotypes of P. vivax in two endemic districts of Nepal. Manandhar S; Bhusal CL; Ghimire U; Singh SP; Karmacharya DB; Dixit SM Malar J; 2013 Sep; 12():324. PubMed ID: 24041296 [TBL] [Abstract][Full Text] [Related]
32. Population-level estimates of the proportion of Plasmodium vivax blood-stage infections attributable to relapses among febrile patients attending Adama Malaria Diagnostic Centre, East Shoa Zone, Oromia, Ethiopia. Golassa L; White MT Malar J; 2017 Jul; 16(1):301. PubMed ID: 28750669 [TBL] [Abstract][Full Text] [Related]
34. Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases. de Pina-Costa A; Silvino ACR; Dos Santos EM; Pedro RS; Moreira J; Umana GL; da Silva ADT; da Rosa Santos OHL; de Deus Henriques KM; Daniel-Ribeiro CT; Brasil P; Sousa TN; Siqueira AM Malar J; 2021 Aug; 20(1):341. PubMed ID: 34391426 [TBL] [Abstract][Full Text] [Related]
35. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms. Baird JK; Battle KE; Howes RE Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870 [TBL] [Abstract][Full Text] [Related]
37. Polymorphism analysis of propeller domain of k13 gene in Plasmodium ovale curtisi and Plasmodium ovale wallikeri isolates original infection from Myanmar and Africa in Yunnan Province, China. Chen M; Dong Y; Deng Y; Xu Y; Liu Y; Zhang C; Huang H Malar J; 2020 Jul; 19(1):246. PubMed ID: 32660505 [TBL] [Abstract][Full Text] [Related]
38. Monitoring Plasmodium vivax chloroquine sensitivity along China-Myanmar border of Yunnan Province, China during 2008-2013. Liu H; Yang HL; Tang LH; Li XL; Huang F; Wang JZ; Li CF; Wang HY; Nie RH; Guo XR; Lin YX; Li M; Xu JW Malar J; 2014 Sep; 13():364. PubMed ID: 25224069 [TBL] [Abstract][Full Text] [Related]
39. Transmission dynamics of co-endemic Plasmodium vivax and P. falciparum in Ethiopia and prevalence of antimalarial resistant genotypes. Lo E; Hemming-Schroeder E; Yewhalaw D; Nguyen J; Kebede E; Zemene E; Getachew S; Tushune K; Zhong D; Zhou G; Petros B; Yan G PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005806. PubMed ID: 28746333 [TBL] [Abstract][Full Text] [Related]
40. Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis. Park YA; Park KH; Yoon HY; Yee J; Gwak HS Travel Med Infect Dis; 2022; 48():102333. PubMed ID: 35452835 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]